Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer ; volume:56 ; number:5 ; day:1 ; month:5 ; year:2024 ; pages:1137-1149 ; date:5.2024
Experimental & molecular medicine ; 56, Heft 5 (1.5.2024), 1137-1149, 5.2024
- Urheber
-
Park, Wonyoung
Wei, Shibo
Xie, Chu-Long
Han, Jung Ho
Kim, Bo-Sung
Kim, Bosung
Jin, Jung-Sook
Yang, Eun-Sun
Cho, Min Kyoung
Ryu, Dongryeol
Yang, Hao-Xian
Bae, Sung-Jin
Ha, Ki-Tae
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s12276-024-01221-2
- URN
-
urn:nbn:de:101:1-2408102121589.121074817310
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.04.2029, 16:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Park, Wonyoung
- Wei, Shibo
- Xie, Chu-Long
- Han, Jung Ho
- Kim, Bo-Sung
- Kim, Bosung
- Jin, Jung-Sook
- Yang, Eun-Sun
- Cho, Min Kyoung
- Ryu, Dongryeol
- Yang, Hao-Xian
- Bae, Sung-Jin
- Ha, Ki-Tae
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin
Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection
Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin
Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection
Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Escherichia coli aceE variants coding pyruvate dehydrogenase improve the generation of pyruvate‐derived acetoin
Upregulation of pyruvate dehydrogenase kinase 4 enhances hepatocyte chemoprotection
Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells